Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss how medical mistrust has impacted participation in oncology clinical trials.

Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...

Yet, this lack of bespoke options is more or less the reality of medicine today. Despite the many biological differences between people of different genders, races, ages and life histories, chances ...

Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...

Objectives This study evaluated the representation of black researchers as authors of articles published in four ...

February is American Heart Month, a highlight of which is Wear Red Day, which aims to raise awareness about heart disease in ...

The study revealed a lack of equitable representation in trials of head and neck cancer. Oncologists can help by ensuring that all their patients are screened for clinical trial eligibility.

The FDA's removal of draft guidance on clinical trial diversity raises concerns about ... will evaluate Diversity Action Plans required under the Food and Drug Omnibus Reform Act (FDORA ...

The Diversity Action Plan, required by the 2022 Food and Drug Omnibus Reform Act, seeks to address the lack of minority representation in clinical trials. The guidance mandates drug and device ...

Although these patients were eligible for recent prospective randomized trials, few ultimately were enrolled. We sought to compare the expected percentage of MM versus No MM encountered in clinical ...

If better representation in clinical trials reduces health disparities by even a modest amount, the analysis found that achieving diverse representation in research would be worth billions of ...